Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siponimod versus placebo in secondary progressive multiple sclerosis
NL-OMON53018Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of siponimod in secondary-progressive multiple sclerosis (SPMS) (3 arms), sponsored by Novartis. Primary endpoint: Time to 3-month confirmed disability progression. Started Jan 2013; status: active, not recruiting.
02
Drugs
siponimod
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NL-OMON53018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53018.